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In January 2004, after my first 3 years as Editor-in-Chief of
Cardiovascular Drugs and Therapy (CDT), I wrote in the
Editor’s page, that these first years had been good for the
journal and that I looked forward to the years to come.
A second 3-year period has passed—and the question is
what have we achieved?
Is there still a reason to be content?
I believe, there is. We have received a steadily rising
number of articles, and with that a steadily increase in
critical appreciation of quality and suitability for publica-
tion. As a consequence, and in order to stay within the
limits of available pages in each issue, rejection rate has
increased, However, in parallel, so did our citation index.
Another reason to be content regards the speed of the
reviewing process. This has considerably shortened com-
pared to the previous 3 years, partly due to few reviewer
refusals, a fast return of reviews, and the easiness of the on-
line review system with our new Editorial Manager System.
The average review time in 2005 was 18 days.
Moreover, in the past years, CDT has become available
on-line and is often visited with a very satisfying number of
full text articles viewed. This is particularly true for the new
Online First, where articles become available in PDF
format the moment they are accepted, well before publica-
tion in the regular paper issue of the journal.
That CDT is doing well has many reasons. The input and
support of the Editorial Board, in particular that of the
Associate and Section Editors, is a very important one, and
I am very grateful for their help.
Moreover, as mentioned above, I cannot complain about
reviewer support. I have been always happily surprised by
the positive responses to our request to review and I want to
thank again all those who reviewed in the last 3 years.
Also, I am much obliged to all who accepted to write
editorials. These have undoubtedly contributed much to the
standing of CDT.
One person deserves to be mentioned by name and that
is my excellent Editorial Assistant Noor van Dam, who is
really the central and most important person in our Editorial
Office, and without whom I would be rather helpless.
A new board and a new approach
The overriding aim of an Editorial Board and its Editor-
in-Chief is to improve the quality and standing of the
journal at hand. And so it is with CDT.
The Editorial Board has decided to make certain changes
in the direction of the Journal. CDT is doing well with a
steadily rising citation index. Still, this could be much
improved if certain “niche” roles could be found for CDT in
the coming years.
Currently, its aim is very broad, and we consider that if
the journal were to be recognised by its focus on
translational research in specific areas in addition to review
and teaching articles pertinent to these areas, that this will
help to improve its impact further.
Whereas we will continue with the current lay-out, which
I believe works well, i.e. the 4sections: Basic Pharmacology,
Clinical Pharmacology and Drug Studies, Clinical Trials,
and Pharmaco-economics and-epidemiology, new sections
pertaining to the changes mentioned above will be added.
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be included. Devices have become progressively important
in the management of various cardiovascular disease areas;
there is in many ways an interaction with pharmacological
therapy and it is therefore inappropriate and unwise to
exclude them in a journal devoted to cardiovascular disease
management and to focus only on drugs.
To ensure optimal handling of these new developments,
both the structure and composition of the Editorial Board
has been drastically changed.
First, a larger core group of Associate and Section
Editors was assembled with the aim of covering the most
important cardiovascular disease areas for CDT, global
representation and to ensure a high degree of expertise in
the day to day management of the journal. I am happy to
say that all Associate and Section Editors have enthusias-
tically responded to my request to function in their
respective positions. Their input will be of crucial impor-
tance for the success of CDT and I look forward to working
with them.
Second, several Board members who have held key
positions in the Board for many years will remain as Senior
Advisory Editors. Their knowledge of Board matters and
experience cannot be missed. Their advice on matters
relating to direction and content of the journal will regularly
be sought.
Third, it is natural that after several years on the Editorial
Board some members will stand down. I take this
opportunity to thank them for their support of the journal.
One person who I cannot thank anymore, but who has
been of great value and inspiration for the journal and the
ISCP, and who was a personal friend, is Ariel Reyes, who
tragically died suddenly in August 2006. An obituary
written by one of his closest friend can be found in this
issue of CDT.
Fourth, many new Board members have joined, all of
whom have shown a significant interest in and affiliation
with the journal and were selected for their expertise in a
specific cardiovascular pharmacological or clinical area. It
is with much pleasure that I welcome them. I am certain
that their contribution as Editorial Board members will
further improve the journal.
While the years 2001–2003 signalled a good start and
2004–2006 showed a steady improvement, I am confident
that this tendency will continue, but at a faster speed.
I look forward to even better years to come.
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